Skip to Content
MilliporeSigma
  • In vitro extracorporeal shock wave treatment enhances stemness and preserves multipotency of rat and human adipose-derived stem cells.

In vitro extracorporeal shock wave treatment enhances stemness and preserves multipotency of rat and human adipose-derived stem cells.

Cytotherapy (2014-09-02)
Christina Maria Anna Pia Schuh, Philipp Heher, Anna Maria Weihs, Asmita Banerjee, Christiane Fuchs, Christian Gabriel, Susanne Wolbank, Rainer Mittermayr, Heinz Redl, Dominik Rünzler, Andreas Herbert Teuschl
ABSTRACT

Adipose-derived progenitor/stem cells (ASCs) are discussed as a promising candidate for various tissue engineering approaches. However, its applicability for the clinic is still difficult due to intra- and inter-donor heterogeneity and limited life span in vitro, influencing differentiation capacity as a consequence to decreased multipotency. Extracorporeal shock wave treatment has been proven to be a suitable clinical tool to improve regeneration of a variety of tissues for several decades, whereas the mechanisms underlying these beneficial effects remain widely unknown. In this study we show that human and rat adipose derived stem cells respond strongly to repetitive shock wave treatment in vitro, resulting not only in maintenance and significant elevation of mesenchymal markers (CD73, CD90, CD105), but also in significantly increased differentiation capacity towards the osteogenic and adipogenic lineage as well as toward Schwann-cell like cells even after extended time in vitro, preserving multipotency of ASCs. ESWT might be a promising tool to improve ASC quality for cell therapy in various tissue engineering and regenerative medicine applications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-RPLP0 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Hydrocortisone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dimethyl sulfoxide, Vetec, reagent grade, 99%
Sigma-Aldrich
Dimethyl sulfoxide, puriss. p.a., dried, ≤0.02% water
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Dimethyl sulfoxide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dimethyl sulfoxide, suitable for HPLC
Sigma-Aldrich
Dimethyl sulfoxide, ≥99.0%, suitable for absorption spectrum analysis
Sigma-Aldrich
Dimethyl sulfoxide, JIS special grade, ≥99.0%
Sigma-Aldrich
Dimethyl sulfoxide, SAJ first grade, ≥99.0%
Sigma-Aldrich
Dimethyl sulfoxide solution, 50 wt. % in H2O
Sigma-Aldrich
Dimethyl sulfoxide, ≥99.5%
Sigma-Aldrich
FGF-2 human, recombinant, expressed in insect cells, ≥85% (SDS-PAGE)
Sigma-Aldrich
Hematoxylin, certified by the Biological Stain Commission
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Sodium carbonate-12C, 99.9 atom % 12C
Sigma-Aldrich
Forskolin, from Coleus forskohlii, ≥98% (HPLC), powder
Supelco
Forskolin, analytical standard
Sigma-Aldrich
Sodium thiosulfate, purum p.a., anhydrous, ≥98.0% (RT)
Supelco
Sodium carbonate concentrate, 0.1 M Na2CO3 in water, eluent concentrate for IC
Supelco
Sodium carbonate concentrate, Na2CO3 72 mM in water, IC eluent concentrate (20x) for Metrosep A Supp 7
USP
Dimethyl sulfoxide, United States Pharmacopeia (USP) Reference Standard
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
FGF-2 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Sigma-Aldrich
Sodium thiosulfate, ≥99.99% trace metals basis
Sigma-Aldrich
Dimethyl sulfoxide, puriss. p.a., ACS reagent, ≥99.9% (GC)